The role of pharmacogenetics in nonmalignant gastrointestinal diseases

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Genetic variation influences the absorption and efflux of drugs in the intestine, the metabolism of drugs in the liver and the effects of these drugs on their target proteins. Indeed, variations in genes whose products have a role in the pathophysiology of nonmalignant gastrointestinal diseases, such as IBD, have been shown to affect the response of patients to therapy. This Review provides an overview of pharmacogenetics in the management of nonmalignant gastrointestinal diseases on the basis of data from clinical trials. Genetic variants that have the greatest effect on the management of patients with IBD involve the metabolism of thiopurines. Variation in drug metabolism by cytochrome P450 enzymes also requires attention so as to avoid drug interactions in patients receiving tricyclic antidepressants and PPIs. Few genotyping tests are currently used in the clinical management of patients with nonmalignant gastrointestinal diseases, owing to a lack of data from clinical trials showing their effectiveness in predicting nonresponse or adverse outcomes. However, pharmacogenetics could have a beneficial role in enabling pharmacotherapy for nonmalignant gastrointestinal diseases to be targeted to the individual patient.

Original languageEnglish (US)
Pages (from-to)173-184
Number of pages12
JournalNature Reviews Gastroenterology and Hepatology
Volume9
Issue number3
DOIs
StatePublished - Mar 2012

Fingerprint

Gastrointestinal Diseases
Pharmacogenetics
Pharmaceutical Preparations
Cytochrome P-450 Enzyme System
Clinical Trials
Tricyclic Antidepressive Agents
Drug Interactions
Intestines
Drug Therapy
Liver
Genes
Proteins

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

The role of pharmacogenetics in nonmalignant gastrointestinal diseases. / Camilleri, Michael.

In: Nature Reviews Gastroenterology and Hepatology, Vol. 9, No. 3, 03.2012, p. 173-184.

Research output: Contribution to journalArticle

@article{16bbc7d1a99045aea26e71a227340c2f,
title = "The role of pharmacogenetics in nonmalignant gastrointestinal diseases",
abstract = "Genetic variation influences the absorption and efflux of drugs in the intestine, the metabolism of drugs in the liver and the effects of these drugs on their target proteins. Indeed, variations in genes whose products have a role in the pathophysiology of nonmalignant gastrointestinal diseases, such as IBD, have been shown to affect the response of patients to therapy. This Review provides an overview of pharmacogenetics in the management of nonmalignant gastrointestinal diseases on the basis of data from clinical trials. Genetic variants that have the greatest effect on the management of patients with IBD involve the metabolism of thiopurines. Variation in drug metabolism by cytochrome P450 enzymes also requires attention so as to avoid drug interactions in patients receiving tricyclic antidepressants and PPIs. Few genotyping tests are currently used in the clinical management of patients with nonmalignant gastrointestinal diseases, owing to a lack of data from clinical trials showing their effectiveness in predicting nonresponse or adverse outcomes. However, pharmacogenetics could have a beneficial role in enabling pharmacotherapy for nonmalignant gastrointestinal diseases to be targeted to the individual patient.",
author = "Michael Camilleri",
year = "2012",
month = "3",
doi = "10.1038/nrgastro.2012.2",
language = "English (US)",
volume = "9",
pages = "173--184",
journal = "Nature Reviews Gastroenterology and Hepatology",
issn = "1759-5045",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - The role of pharmacogenetics in nonmalignant gastrointestinal diseases

AU - Camilleri, Michael

PY - 2012/3

Y1 - 2012/3

N2 - Genetic variation influences the absorption and efflux of drugs in the intestine, the metabolism of drugs in the liver and the effects of these drugs on their target proteins. Indeed, variations in genes whose products have a role in the pathophysiology of nonmalignant gastrointestinal diseases, such as IBD, have been shown to affect the response of patients to therapy. This Review provides an overview of pharmacogenetics in the management of nonmalignant gastrointestinal diseases on the basis of data from clinical trials. Genetic variants that have the greatest effect on the management of patients with IBD involve the metabolism of thiopurines. Variation in drug metabolism by cytochrome P450 enzymes also requires attention so as to avoid drug interactions in patients receiving tricyclic antidepressants and PPIs. Few genotyping tests are currently used in the clinical management of patients with nonmalignant gastrointestinal diseases, owing to a lack of data from clinical trials showing their effectiveness in predicting nonresponse or adverse outcomes. However, pharmacogenetics could have a beneficial role in enabling pharmacotherapy for nonmalignant gastrointestinal diseases to be targeted to the individual patient.

AB - Genetic variation influences the absorption and efflux of drugs in the intestine, the metabolism of drugs in the liver and the effects of these drugs on their target proteins. Indeed, variations in genes whose products have a role in the pathophysiology of nonmalignant gastrointestinal diseases, such as IBD, have been shown to affect the response of patients to therapy. This Review provides an overview of pharmacogenetics in the management of nonmalignant gastrointestinal diseases on the basis of data from clinical trials. Genetic variants that have the greatest effect on the management of patients with IBD involve the metabolism of thiopurines. Variation in drug metabolism by cytochrome P450 enzymes also requires attention so as to avoid drug interactions in patients receiving tricyclic antidepressants and PPIs. Few genotyping tests are currently used in the clinical management of patients with nonmalignant gastrointestinal diseases, owing to a lack of data from clinical trials showing their effectiveness in predicting nonresponse or adverse outcomes. However, pharmacogenetics could have a beneficial role in enabling pharmacotherapy for nonmalignant gastrointestinal diseases to be targeted to the individual patient.

UR - http://www.scopus.com/inward/record.url?scp=84858081488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858081488&partnerID=8YFLogxK

U2 - 10.1038/nrgastro.2012.2

DO - 10.1038/nrgastro.2012.2

M3 - Article

C2 - 22310916

AN - SCOPUS:84858081488

VL - 9

SP - 173

EP - 184

JO - Nature Reviews Gastroenterology and Hepatology

JF - Nature Reviews Gastroenterology and Hepatology

SN - 1759-5045

IS - 3

ER -